PTGS2 as a Radioligand Therapy Target
PTGS2, prostaglandin-endoperoxide synthase 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PTGS2 staining is highest in endometrial cancer (92% of samples positive), bladder cancer (92% of samples positive) and cervical cancer (75% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is PTGS2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in endometrial cancer, 92% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
PTGS2 expression in cancer
Protein expression of PTGS2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Endometrial Cancer | 0.67 | High | 92% |
| Bladder Cancer | 0.58 | High | 92% |
| Cervical Cancer | 0.47 | Medium | 75% |
| Pancreatic Cancer | 0.47 | Medium | 67% |
| Lung Cancer | 0.39 | Medium | 75% |
| Glioma | 0.36 | Medium | 75% |
| Ovarian Cancer | 0.29 | Medium | 63% |
| Skin Cancer | 0.27 | Medium | 64% |
| Prostate Cancer | 0.27 | Medium | 55% |
| Liver Cancer | 0.26 | Medium | 44% |
| Gastric Cancer | 0.25 | Medium | 42% |
| Head and Neck Cancer | 0.25 | Medium | 25% |
| Thyroid Cancer | 0.22 | Medium | 33% |
| Colorectal Cancer | 0.17 | Low | 42% |
| Melanoma | 0.17 | Low | 30% |
| Breast Cancer | 0.15 | Low | 46% |
| Neuroendocrine Tumors | 0.08 | Low | 25% |
| Testicular Cancer | 0.03 | Low | 9% |
Not detected by IHC in: lymphoma, kidney cancer.
Is PTGS2 internalized?
Nuclens has not yet extracted internalization evidence for PTGS2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
PTGS2 clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for PTGS2 yet. Search ClinicalTrials.gov for PTGS2 trials.
PTGS2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PTGS2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
PTGS2 gene essentiality (DepMap)
CRISPR knockout effect across 1254 cancer cell lines: 0.08 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related endometrial cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · B7-H3 (CD276) · SSTR2 · ITGAV · STEAP2
See all radioligand therapy targets in endometrial cancer.
See how PTGS2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.